Bellemin Jean-Marc
Known title: Chief Financial OfficerCIK: 0001754253
Associated companies
Transaction History
| IOVA | ▲ Buy | Option Exercise | 8,789 | $0 | 6/2/2025 | View on chart |
| IOVA | ▼ Sell | Tax Withholding | 4,464 | $8K | 6/2/2025 | View on chart |
| IOVA | ▲ Buy | Option Exercise | 58,590 | $0 | 3/3/2025 | View on chart |
| IOVA | ▼ Sell | Tax Withholding | 31,734 | $128K | 3/3/2025 | View on chart |
| IOVA | ▲ Buy | Option Exercise | 23,438 | $0 | 9/3/2024 | View on chart |
| IOVA | ▼ Sell | Tax Withholding | 11,891 | $129K | 9/3/2024 | View on chart |
| IOVA | ▲ Buy | Option Exercise | 18,850 | $0 | 1/3/2023 | View on chart |
| IOVA | ▼ Sell | Tax Withholding | 10,553 | $64K | 1/3/2023 | View on chart |
| IOVA | ▲ Buy | Option Exercise | 18,850 | $0 | 6/14/2022 | View on chart |
| IOVA | ▼ Sell | Tax Withholding | 9,346 | $72K | 6/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Iovance Biotherapeutics sees analyst target raise and whale activity
Recent reports show large investors were active in IOVA shares, indicating heightened interest. Baird kept a neutral stance but lifted its price target to $11, above its prior level. The Q2 2026 earnings call highlighted ongoing clinical progress, which aligns with the analyst’s revised outlook. The stock is near the upper end of its 52‑week range.
Iovance Biotherapeutics sees analyst target raise and whale activity. Recent reports show large investors were active in IOVA shares, indicating heightened interest. Baird kept a neutral stance but lifted its price target to $11, above its prior level. The Q2 2026 earnings call highlighted ongoing clinical progress, which aligns with the analyst’s revised outlook. The stock is near the upper end of its 52‑week range.